title: Current status of clinically available bioresorbable scaffolds in percutaneous coronary interventions.
abstract: Drug-eluting stents (DES) are widely used as first choice devices in percutaneous coronary interventions. However, certain concerns are associated with the use of DES, i.e. delayed arterial healing with a subsequent risk of neo-atherosclerosis, late stent thrombosis and hypersensitivity reactions to the DES polymer. Bioresorbable vascular scaffolds are the next step in percutaneous coronary interventions introducing the concept of supporting the natural healing process following initial intervention without leaving any foreign body materials resulting in late adverse events. The first-generation devices have shown encouraging results in multiple studies of selected patients up to the point of full bioresorption, supporting the introduction in regular patient care. During its introduction in daily clinical practice outside the previously selected patient groups, a careful approach should be followed in which outcome is continuously monitored.
authors: Department of Cardiology, Thoraxcentre, Room Ba-585, Erasmus University Medical Centre, 'S-Gravendijkwal 230, 3015, Rotterdam, GE, The Netherlands, c.felix@erasmusmc.nl.
authors: Cordula
authors: C
authors: Felix
authors: Bert
authors: B
authors: Everaert
authors: Roberto
authors: R
authors: Diletti
authors: Nicolas
authors: N
authors: Van Mieghem
authors: Joost
authors: J
authors: Daemen
authors: Marco
authors: M
authors: Valgimigli
authors: Peter P
authors: PP
authors: de Jaegere
authors: Felix
authors: F
authors: Zijlstra
authors: Evelyn
authors: E
authors: Regar
authors: Cihan
authors: C
authors: Simsek
authors: Yoshinobu
authors: Y
authors: Onuma
authors: Robert-Jan M
authors: RJ
authors: van Geuns
references: Eur Heart J. 2014 Mar;35(12):777-86
references: 24394380
references: Catheter Cardiovasc Interv. 2007 Oct 1;70(4):515-23
references: 17503509
references: Circulation. 2012 May 15;125(19):2343-53
references: 22508795
references: JACC Cardiovasc Interv. 2014 Jan;7(1):89-99
references: 24139932
references: Neth Heart J. 2015 Mar;23(3):161-5
references: 25626696
references: EuroIntervention. 2015 Jun;11(2):149-56
references: 25499836
references: Neth Heart J. 2014 Nov;22(11):484-90
references: 25200324
references: EuroIntervention. 2015 Apr;10(12):1396-401
references: 24769555
references: Lancet. 2009 Mar 14;373(9667):897-910
references: 19286089
references: J Am Coll Cardiol. 2006 Jul 4;48(1):193-202
references: 16814667
references: EuroIntervention. 2015 Feb;10(10):1160-8
references: 25136885
references: Eur Heart J. 2014 Mar;35(12):765-76
references: 24366915
references: Neth Heart J. 2014 Feb;22(2):55-61
references: 24072688
references: JACC Cardiovasc Interv. 2013 Oct;6(10 ):999-1009
references: 24156961
references: Lancet. 2015 Jan 3;385(9962):43-54
references: 25230593
references: Clin Res Cardiol. 2014 Feb;103(2):141-8
references: 24136291
references: J Am Coll Cardiol. 2011 Oct 4;58(15):1578-88
references: 21958884
references: EuroIntervention. 2014 Jan 22;9(9):1036-41
references: 23999237
references: EuroIntervention. 2014 Mar 20;9(11):1271-84
references: 24291783
references: Catheter Cardiovasc Interv. 2015 Jan 1;85(1):E10-5
references: 24909303
references: EuroIntervention. 2015 Feb;10(10):1144-53
references: 25042421
references: Am Heart J. 2012 Nov;164(5):654-63
references: 23137495
references: J Am Coll Cardiol. 2014 Dec 9;64(22):2343-56
references: 25465421
references: Pol Arch Med Wewn. 2014;124(12 ):669-77
references: 25563622
references: Circ Cardiovasc Interv. 2012 Oct;5(5):620-32
references: 23048057
references: Eur Heart J. 2014 Mar;35(12):787-94
references: 24419808
references: N Engl J Med. 2007 Nov 15;357(20):2001-15
references: 17982182